WCM Investment Management
BBIO icon

WCM Investment Management’s BridgeBio Pharma BBIO Stock Holding History

WCM Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
165,133
-2,850
-2% -$200K 0.02% 143
2026
Q1 		$11.7M Sell
167,983
-6,605
-4% -$479K 0.03% 135
2025
Q4 		$13.2M Sell
174,588
-86,394
-33% -$5.67M 0.03% 135
2025
Q3 		$13.6M Sell
260,982
-14,253
-5% -$695K 0.03% 129
2025
Q2 		$12.3M Buy
275,235
+17,133
+7% +$623K 0.03% 137
2025
Q1 		$9.06M Sell
258,102
-3,842
-1% -$130K 0.02% 147
2024
Q4 		$7.16M Sell
261,944
-1,735
-0.7% -$44.8K 0.02% 163
2024
Q3 		$6.58M Buy
263,679
+86,987
+49% +$2.28M 0.01% 160
2024
Q2 		$4.45M Buy
176,692
+2,766
+2% +$75.6K 0.01% 166
2024
Q1 		$5.38M Sell
173,926
-117,717
-40% -$4M 0.01% 157
2023
Q4 		$12.2M Buy
291,643
+7,156
+3% +$215K 0.03% 136
2023
Q3 		$7.5M Buy
284,487
+5,833
+2% +$166K 0.02% 140
2023
Q2 		$4.79M Sell
278,654
-93,934
-25% -$1.41M 0.01% 159
2023
Q1 		$6.18M Buy
372,588
+4,797
+1% +$55.9K 0.02% 149
2022
Q4 		$2.8M Sell
367,791
-4,641
-1% -$44.4K 0.01% 178
2022
Q3 		$3.8M Buy
372,432
+29,363
+9% +$305K 0.01% 151
2022
Q2 		$3.03M Buy
343,069
+212
+0.1% +$1.77K 0.01% 160
2022
Q1 		$3.48M Buy
342,857
+216,587
+172% +$2.22M 0.01% 154
2021
Q4 		$2.11M Buy
126,270
+60,766
+93% +$2.57M ﹤0.01% 166
2021
Q3 		$3.07M Buy
65,504
+482
+0.7% +$25.8K 0.01% 160
2021
Q2 		$3.96M Sell
65,022
-40,406
-38% -$2.31M 0.01% 143
2021
Q1 		$6.49M Sell
105,428
-36,421
-26% -$2.38M 0.02% 131
2020
Q4 		$10.1M Buy
141,849
+36,053
+34% +$1.74M 0.03% 111
2020
Q3 		$3.97M Buy
105,796
+6,523
+7% +$205K 0.01% 143
2020
Q2 		$3.24M Buy
99,273
+33,050
+50% +$1.01M 0.01% 145
2020
Q1 		$1.92M Buy
+66,223
New +$2.05M 0.01% 151

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

WCM Investment Management's BBIO Position: Q2 2026 in Review

WCM Investment Management reduced its BridgeBio Pharma (BBIO) stake by 1.7% in Q2 2026, selling an estimated $200K and leaving 165,133 shares worth $11.9M. The position accounts for 0.02% of the portfolio, ranked #143.

WCM Investment Management first reported a position in BBIO in Q1 2020 and has held it in 26 quarters since. The position peaked at $13.6M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • WCM Investment Management held 165,133 shares of BridgeBio Pharma worth $11.9M as of Q2 2026.
  • WCM Investment Management sold 2,850 BridgeBio Pharma shares in Q2 2026, an estimated $200K.
  • BridgeBio Pharma made up 0.02% of WCM Investment Management's portfolio in Q2 2026, its #143 holding.
  • WCM Investment Management first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 26 quarters since.
  • WCM Investment Management's BridgeBio Pharma position peaked at $13.6M in Q3 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on WCM Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.